Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors

Full metadata record
DC Field Value Language
dc.contributor.authorAbdelazem, A.Z.-
dc.contributor.authorAl-Sanea, M.M.-
dc.contributor.authorPark, B.S.-
dc.contributor.authorPark, H.M.-
dc.contributor.authorYoo, K.H.-
dc.contributor.authorSim, T.-
dc.contributor.authorPark, J.B.-
dc.contributor.authorLee, S.-H.-
dc.contributor.authorLee, S.H.-
dc.date.accessioned2021-09-04T23:52:12Z-
dc.date.available2021-09-04T23:52:12Z-
dc.date.created2021-06-17-
dc.date.issued2015-
dc.identifier.issn0223-5234-
dc.identifier.urihttps://scholar.korea.ac.kr/handle/2021.sw.korea/95891-
dc.description.abstractWith the aim of discovering potent and selective kinase inhibitors targeting ROS1 kinase, we designed, synthesized and screened a series of new pyrazol-4-ylpyrimidine derivatives based on our previously discovered lead compound KIST301072. Compounds 6a-e and 7a-e showed good to excellent activities against ROS1 kinase, and seven out of tested compounds were more potent than KIST301072. Compound 7c was the most potent with IC<inf>50</inf> of 24 nM. Moreover, compound 7c showed ROS1 inhibitory selectivity of about 170-fold, relative to that of ALK sharing about 49% amino acid sequence homology with ROS1 kinase in the kinase domain. In silico modeling of 7c at ROS1 active site revealed some essential features for ROS1 inhibitory activity. Based on this study as well as the previous studies, we could build a hypothetical model predicting the required essential features for ROS1 inhibitory activity. The model validity has been tested through a second set of compounds. © 2014 Elsevier Masson SAS.-
dc.languageEnglish-
dc.language.isoen-
dc.publisherElsevier Masson SAS-
dc.subject2 [3 (3 hydroxy 5 methylphenyl) 4 [6 (isobutylamino) 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(2 morpholinoethyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(3 morpholinopropyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(4 hydroxybutyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [3 (3 methoxy 5 methylphenyl) 4 [6 [(2 morpholinoethyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [3 (3 methoxy 5 methylphenyl) 4 [6 [(3 morpholinopropyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject2 [4 [6 (3 hydroxypropylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subject2 [4 [6 (4 hydroxypropylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subject2 [4 [6 (isobutylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subjectprotein tyrosine kinase inhibitor-
dc.subjectpyrazol 4 ylpyrimidine derivative-
dc.subjectunclassified drug-
dc.subjectprotein kinase inhibitor-
dc.subjectprotein tyrosine kinase-
dc.subjectpyrazol-4-ylpyrimidine-
dc.subjectpyrazole derivative-
dc.subjectpyrimidine derivative-
dc.subjectamino acid sequence-
dc.subjectArticle-
dc.subjectbiological activity-
dc.subjectdrug activity-
dc.subjectdrug design-
dc.subjectdrug potency-
dc.subjectdrug screening-
dc.subjectdrug structure-
dc.subjectdrug synthesis-
dc.subjectenzyme inhibition-
dc.subjectIC50-
dc.subjectsequence homology-
dc.subjectantagonists and inhibitors-
dc.subjectchemical structure-
dc.subjectchemistry-
dc.subjectdose response-
dc.subjecthuman-
dc.subjectmetabolism-
dc.subjectstructure activity relation-
dc.subjectsynthesis-
dc.subjectDose-Response Relationship, Drug-
dc.subjectHumans-
dc.subjectModels, Molecular-
dc.subjectMolecular Structure-
dc.subjectProtein Kinase Inhibitors-
dc.subjectPyrazoles-
dc.subjectPyrimidines-
dc.subjectReceptor Protein-Tyrosine Kinases-
dc.subjectStructure-Activity Relationship-
dc.titleSynthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors-
dc.typeArticle-
dc.contributor.affiliatedAuthorSim, T.-
dc.identifier.doi10.1016/j.ejmech.2014.11.023-
dc.identifier.scopusid2-s2.0-84911399882-
dc.identifier.bibliographicCitationEuropean Journal of Medicinal Chemistry, v.90, pp.195 - 208-
dc.relation.isPartOfEuropean Journal of Medicinal Chemistry-
dc.citation.titleEuropean Journal of Medicinal Chemistry-
dc.citation.volume90-
dc.citation.startPage195-
dc.citation.endPage208-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.subject.keywordPlus2 [3 (3 hydroxy 5 methylphenyl) 4 [6 (isobutylamino) 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(2 morpholinoethyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(3 morpholinopropyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [3 (3 hydroxy 5 methylphenyl) 4 [6 [(4 hydroxybutyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [3 (3 methoxy 5 methylphenyl) 4 [6 [(2 morpholinoethyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [3 (3 methoxy 5 methylphenyl) 4 [6 [(3 morpholinopropyl)amino] 2 (pyridin 3 yl)pyrimidine 4 yl] 1h pyrazol 1 yl]acetonitrile-
dc.subject.keywordPlus2 [4 [6 (3 hydroxypropylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subject.keywordPlus2 [4 [6 (4 hydroxypropylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subject.keywordPlus2 [4 [6 (isobutylamino) 2 (pyridin 3 yl)pyrimidin 4 yl] 3 (3 methoxy 5 methylphenyl) 1h pyrazol 1 yl]acetinitrile-
dc.subject.keywordPlusprotein tyrosine kinase inhibitor-
dc.subject.keywordPluspyrazol 4 ylpyrimidine derivative-
dc.subject.keywordPlusunclassified drug-
dc.subject.keywordPlusprotein kinase inhibitor-
dc.subject.keywordPlusprotein tyrosine kinase-
dc.subject.keywordPluspyrazol-4-ylpyrimidine-
dc.subject.keywordPluspyrazole derivative-
dc.subject.keywordPluspyrimidine derivative-
dc.subject.keywordPlusamino acid sequence-
dc.subject.keywordPlusArticle-
dc.subject.keywordPlusbiological activity-
dc.subject.keywordPlusdrug activity-
dc.subject.keywordPlusdrug design-
dc.subject.keywordPlusdrug potency-
dc.subject.keywordPlusdrug screening-
dc.subject.keywordPlusdrug structure-
dc.subject.keywordPlusdrug synthesis-
dc.subject.keywordPlusenzyme inhibition-
dc.subject.keywordPlusIC50-
dc.subject.keywordPlussequence homology-
dc.subject.keywordPlusantagonists and inhibitors-
dc.subject.keywordPluschemical structure-
dc.subject.keywordPluschemistry-
dc.subject.keywordPlusdose response-
dc.subject.keywordPlushuman-
dc.subject.keywordPlusmetabolism-
dc.subject.keywordPlusstructure activity relation-
dc.subject.keywordPlussynthesis-
dc.subject.keywordPlusDose-Response Relationship, Drug-
dc.subject.keywordPlusHumans-
dc.subject.keywordPlusModels, Molecular-
dc.subject.keywordPlusMolecular Structure-
dc.subject.keywordPlusProtein Kinase Inhibitors-
dc.subject.keywordPlusPyrazoles-
dc.subject.keywordPlusPyrimidines-
dc.subject.keywordPlusReceptor Protein-Tyrosine Kinases-
dc.subject.keywordPlusStructure-Activity Relationship-
dc.subject.keywordAuthorNon-small cell lung cancer-
dc.subject.keywordAuthorPyrazol-4-ylpyrimidine-
dc.subject.keywordAuthorReceptor tyrosine kinase-
dc.subject.keywordAuthorROS1 kinase inhibitor-
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > KU-KIST Graduate School of Converging Science and Technology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE